Stérilisation tubaire par voie hystéroscopique : faisabilité et évaluation à un an

Gibon, E.; Lopès, P.; Linet, Teddy; Martigny, H.; Orieux, C.; Philippe, H.-J.

doi:10.1016/j.gyobfe.2006.01.029

Cited by 10 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides acute pain and one self-limited vagal reaction, we had no other incidents like perforation, syncope, or infection. In the literature, there is no evidence about acute complication incidence, but our findings and of others support that this procedure is moderately painful even if brief [ 5 – 8 ]. An incidence of 4.2% of pain chronification (lasting more than 3 months after the procedure) has been estimated [ 10 ].…”

Section: Discussionsupporting

confidence: 53%

“…Although there are presently many controversies about Essure®, evidence about long-term follow-up of patients submitted to this type of definitive contraception is scarce. The importance to proceed to an extended survey of patients’ satisfaction has been unanimously strengthened by previous studies [ 5 – 9 ]. In what concerns the demographic findings in our population, they are similar to what has been described by others [ 5 – 9 ].…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have been reported which describe long-term follow-ups (from 1 to 5 years) of patients submitted to sterilization with Essure® [ 5 – 7 ]. In this study, the authors have proceeded to a retrospective consecutive case series analysis of one-center ( two hysteroscopists ), 5 years’ experience with Essure®.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Essure® present controversies and 5 years’ learned lessons: a retrospective study with short- and long-term follow-up

et al. 2017

View full text Add to dashboard Cite

BackgroundThe risk-benefit of contraception with Essure® is being readdressed due to an increase of reports of adverse effects with this device. Our aim was to proceed to an internal quality evaluation and to identify opportunities for protocol improvement.We proceeded to a one-center, retrospective consecutive case series of women admitted for Essure® placement, from 1 January 2012 until 31 December 2016 (5 years).ResultsIn a total of 274 women, technical difficulties were mainly unilateral, with no acute or short-term severe complications. The procedure was brief (median 3.2 min, IQR 2.5–5.2) and moderately painful (median of 4 in a 0–10 scale; IQR 3–5). At 3 months, the failure rate was 2%, with no pregnancies. Second surgery indication (< 1%) resumed to a case of nickel hypersensitivity. At 1 year, pregnancy rate was 1%. Ninety-eight percent of the patients would recommend the method.ConclusionsWe identified high patient satisfaction and low failure rates, both at short and long term. Investigation about whether some women still have patent tubes at the 3-month follow-up could lead to protocol improvement. It is important that clinicians look for second causes for adverse effects related to Essure® and avoid the erroneous indication for implant removal. Long follow-up allowed for both internal quality evaluation and clarification of misconception; it could possibly also have contributed to patient satisfaction.

show abstract

Section: Discussionsupporting

confidence: 53%